drugset / Trial / NCT02144792

Development and Clinical Application of [11C]Verapamil-PET

NCT02144792 ↗

Phase 2 Unknown 30 enrolled Seoul National University Hospital
Non-randomizedSingle-groupOpen-labelDiagnostic

Summary

The major hypothesis explaining drug resistance is overexpression of p-glycoprotein at the target lesion. Based on several studies, p-glycoprotein (P-gp) has an important role in neurologic diseases, especially in drug resistant epilepsy. But there is no surrogate marker that can quantify the expression of P-gp because of the difficulty in measuring substances in the neurologic system and the lack of clinical trials. Here, the investigators use a novel non-invasive \[11C\] -verapamil Brain PET and SPAM analytic method as a surrogate marker for quantifying the expression of p-glycoprotein.

Timeline

Start
2013-05
Primary completion
2014-05
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cyclosporin A Unknown 2.5 mg/kg Intravenous

Indications